Printer Friendly
The Free Library
14,650,879 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

``Enhancing the Therapeutic Utility of Biopharmaceuticals: The Next Frontier''.


Business Editors and Health/Medical Writers

BIOWIRE2K

MONROVIA, Calif.--(BW HealthWire)--June 4, 2002

Xencor's Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in Room

701A.

Xencor, a drug discovery company focused on protein optimization and chemical genomics, today announced that Robert Pacifici, Ph.D., Vice President of Discovery Technologies, will present as a member of the "Enhancing the Therapeutic Utility of Biopharmaceuticals: The Next Frontier" panel during the BIO 2002 International Biotechnology Convention & Exhibition. Panel members will discuss efforts to improve the biophysical and therapeutic properties of current and potential protein therapeutics. Topics will include: emerging technologies in protein optimization, protein modification, developments in drug-delivery technologies and methods to predict and evade e·vade  
v. e·vad·ed, e·vad·ing, e·vades

v.tr.
1. To escape or avoid by cleverness or deceit: evade arrest.

2.
a.
 immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. .

"Protein optimization is the future for biotherapeutics," stated Dr. Pacifici. "Using the information embedded Inserted into. See embedded system.  in protein structure to optimize the function of the protein is crucial in developing the next generation of biopharmaceuticals. Technologies such as Xencor's Protein Design Automation(TM) (PDA (Personal Digital Assistant) A handheld computer for managing contacts, appointments and tasks. It typically includes a name and address database, calendar, to-do list and note taker, which are the functions in a personal information manager (see PIM). (TM)) enable the development of novel biotherapeutics, improved second-generation therapeutic proteins, enzymes with enhanced properties and optimized antibodies."

The panel is chaired by Linda Jolliffe, Ph.D., Vice President, Drug Discovery /Biology, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. In addition to Dr. Pacifici, other speakers will include, David Estell, Ph.D., Research Fellow and Vice President, Technology, Genencor International and B. Michael Silber, Ph.D., Vice President, Research, ALZA Corporation.

"The PDA(TM) platform is the first and only rational, structure-based protein optimization method," added Dr. Pacifici. "It combines advanced computational methods, high performance computing power, and experimental screening to access 70 orders of magnitude more protein sequence diversity than directed evolution Directed evolution is a method used in protein engineering to harness the power of Darwinian selection to evolve proteins or RNA with desirable properties not found in nature.  methods and phage display phage display
n.
A technique using recombinant DNA technology to create bacteriophages with a desired peptide embedded in the surface of their protein shells.
. Our ultra high-throughput capabilities allow us to improve protein properties faster and more efficiently than current methods, while creating new intellectual property."

Xencor discovers and develops protein and small molecule therapeutics using its proprietary rational protein design and chemical biology Chemical biology is a scientific discipline spanning the fields of chemistry and biology that involves the application of chemical techniques and tools, often compounds produced through synthetic chemistry, to the study and manipulation of biological systems.  platforms. Xencor's platforms apply high performance computing and advanced cell biology Cell biology

The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented.
 to rapidly discover drugs with novel mechanisms and improved safety and efficacy. Xencor is a privately held biopharmaceutical company located in Monrovia, CA. Additional information is available at www.xencor.com.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 4, 2002
Words:371
Previous Article:Sorrento Networks Announces Interoperability with Hitachi Telecom USA Inc. Long-Haul Optical Networking Systems.
Next Article:MarineMax Appoints Ernst & Young as Auditor.



Related Articles
Converting nursing homes to subacute: the frontier model. (Boston's Frontier Group)
Hemispherx Biopharma Sponsors Global AIDS Fundraiser at United Nations.
Microbix Named In Special Report Calling Generic Biologics "The Next Frontier".
Insert Therapeutics Inc. Appoints Leonard R. Borrmann, Pharm.D., as President and Chief Executive Officer.
DIATOS AND MEDAREX SIGN CANCER PRODUCT LICENSING AGREEMENT.
ZIOPHARM ZIO-101 Investigator Chairs Session at Gordon Research Conference at University of Oxford.
BIOPARTNERS REMAINS POSITIVE AFTER ALPHENON CHMP RULING.
Roche Acquires THP in $56.5 Million Deal.
FIRST HEART ATTACK PATIENT ENROLLED IN RAPID MI-ICE STUDY.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles